Superior effects of natalizumab versus other DMTs on patient-reported outcomes in people with multiple sclerosis.

Natalizumab was associated with superior outcomes over time for many patient-reported health and employment outcomes when compared with other DMTs in this large prospective cohort study. These findings may influence treatment selection in clinical practice and future treatment cost-effectiveness analyses.